Crossmark Global Holdings Inc. Makes New $275,000 Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Crossmark Global Holdings Inc. bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,018 shares of the biopharmaceutical company's stock, valued at approximately $275,000.

Other institutional investors also recently bought and sold shares of the company. Whipplewood Advisors LLC boosted its holdings in Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 71 shares during the period. Bessemer Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 69 shares during the period. Park Square Financial Group LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at about $28,000. Colonial Trust Co SC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at about $35,000. Finally, Washington Trust Advisors Inc. boosted its holdings in Alnylam Pharmaceuticals by 53.5% during the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 61 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the transaction, the chief executive officer owned 48,948 shares of the company's stock, valued at $14,899,281.72. This trade represents a 39.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Stock Up 0.6%

ALNY stock traded up $1.88 on Thursday, reaching $324.69. 744,559 shares of the company traded hands, compared to its average volume of 853,737. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $333.70. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. The company has a market cap of $42.34 billion, a P/E ratio of -155.35 and a beta of 0.23. The firm has a fifty day simple moving average of $305.09 and a 200-day simple moving average of $270.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The company had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same period last year, the business earned ($0.16) EPS. The firm's quarterly revenue was up 20.2% on a year-over-year basis. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several analyst reports. Citigroup increased their price objective on Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the stock a "buy" rating in a report on Friday, July 11th. Chardan Capital increased their price objective on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. BMO Capital Markets increased their price objective on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a report on Tuesday, June 24th. Finally, Wells Fargo & Company increased their price objective on Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the stock an "equal weight" rating in a report on Monday, June 30th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-two have given a buy rating to the company's stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $346.13.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.